

## PROVINCIAL FUNDING SUMMARY

## Nivolumab (Opdivo) for Metastatic Melanoma

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 18, 2016

This information is current as of September 13, 2017.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Mar 1, 2017	Unresectable stage 3 or stage 4 metastatic melanoma in patients: Ipilimumab naïve, wild type BRAF V600 mutation status. Patients are eligible to receive pembrolizumab or ipilimumab or nivolumab but not sequential use of these agents. Good performance status; Adequate hepatic and renal function; Access to a treatment centre with expertise to manage immune-mediated adverse reactions of nivolumab. BC Cancer Agency Compassionate Access Program (CAP) approval must be obtained.
AB	Funded	Apr 3, 2017	Nivolumab for the treatment of patients with unresectable or metastatic BRAF wild-type melanoma who are previously untreated, with good performance status and who have stable brain metastases (if present). Treatment should continue until unacceptable toxicity or disease progression. Not to be used for the treatment of patients with BRAF V600 mutations positive unresectable or metastatic melanoma. Not to be used for the treatment of patients who have previously received treatment with ipilimumab or pembrolizumab.
SK	Funded	Mar 23, 2017	As a treatment for patients with BRAF wild-type unresectable or metastatic melanoma who are previously untreated, with good performance status and who have stable brain metastases (if present).
MB	Funded	Mar 13, 2017	For the treatment of patients with: - Primary unresectable or metastatic melanoma AND - Confirmed BRAF wild-type AND - A good performance status.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Mar 21, 2017	Treatment for patients with unresectable or metastatic BRAF wild-type melanoma who are previously untreated, with good performance status and who have stable brain metastases (if present).
NS	Funded	Apr 1, 2017	As a single agent treatment option for patients with advanced melanoma (unresectable or metastatic BRAF wild type) who are previously untreated. Patients should have a good performance status and if present stable brain metastases. Treatment duration should continue until unacceptable toxicity or disease progression.
NB	Funded	May 2, 2017	As first line single agent therapy for the treatment of unresectable or metastatic BRAF wild-type melanoma in patients who are previously untreated, with good performance status and, who have stable brain metastases (if present). Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	Aug 3, 2017	Patients with unresectable or metastatic BRAF wild-type melanoma who are previously untreated, with good performance status and who have stable brain metastases (if present). Treatment should continue until unacceptable toxicity or disease progression.
PEI	Under provincial consideration		

*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.